1,721,094 research outputs found
Fractional flow reserve: Current applications and overview of the available data
No full textFlow fractional reserve (FFR) allows to evaluate the functional significance of coronary artery lesions, through the ratio of the mean coronary artery pressure after the stenosis to the mean aortic pressure during maximum hyperemia. The actual widely accepted cut-off value is 0.80. Below this value a coronary lesion is considered significant and therefore it requires invasive revascularization. Several studies [in particular Fractional Flow Reserve vs Angiography for Multivessel Evaluation 1 (FAME-1) and FAME-2] have shown the relationship between FFR measurement and hard end-points (death, myocardial infarction, and urgent revascularization). Consequently, FFR evaluation represents the cornerstone in the decision-making in intermediate coronary lesions. Recent studies paved the way for further applications of FFR evaluation in complex and tricky clinical settings. In this paper, we perform an overview of the data regarding contemporary application of FFR. In particular, we review the use of FFR in: left main intermediate stenoses, serial stenoses, evaluation after stenting, guidance in coronary artery bypass surgery, and acute coronary syndrome. All the data presented in our overview confirm the essential role of FFR assessment in the daily clinical practice. The shift from "operator-dependent" to "FFR-dependent" evaluation in intermediate coronary artery stenosis is of paramount importance in order to improve the prognosis of our patients, through the discrimination of the functional role of every single coronary stenosis
[Arrhythmogenic left ventricular cardiomyopathy: beyond magnetic resonance imaging]
No full textArrhythmogenic left ventricular cardiomyopathy: beyond magnetic resonance imagin
La differenza è nel team o nel dispositivo? Cosa abbiamo imparato dal trial DanGer Shock [Who will make the difference? The team or the device? What we learned from the DanGer Shock trial]
No full textLa differenza è nel team o nel dispositivo?
Cosa abbiamo imparato dal trial DanGer Shoc
The EARLY ACS study
No full textcommento critico alla pubblicazione dei dati dello studio internazione randomizzato early ac
Tissue factor and coagulation factor VII levels during AMI: association with genotype and adverse events
No full textBioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions
No full textcomment about scaffold performance on very long coronary lesion
Operator, Drug or Device: Who Will Break Down Acute Stent Thrombosis?
No full textcommet about the tips and triks to reduce stent thrombosi
Single or high-dose bolus trifiban and sirolimus eluting stent versus abicixamab and bare metal stent in acute myocardial infarction (STRATEGY Study)
No full textAim to asses whether in patients with STEMI the combination of SES with a single high dose bolus tirofiban regime results in similar incidence of death and MI but in a lower rate of TVR after six months
Tirofiban, administered at high dose bolus during coronary angioplasty is highly effective in preventing periprocedural ischemic complications in diabetic patients. Insights into the ADVANCE trial.
No full textPlatelet reactivity is pivotal in the pathogenesis of complications after coronary angioplasty. ADVANCE trial sought to determine whether tirofiban, administered with the high-dose bolus is able to reduce ischemic events in diabetic patients referred for elective or urgent PCI
- …
